EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Growth Hormone Treatment in Patients With KBG Syndrome: Novel Insights, Challenges and Recommendations From Six New Patients and Literature Review

Sietse M Aukema iD, Kim Vandenput iD, Emanuela Scarano iD, Himanshu Goel iD, Lily Guo iD, Michiel Vanneste iD, Koen Devriendt iD, Nitash Zwaveling-Soonawala iD, Cordula Kiewert, Alma Kuechler, Ilaria Parenti iD, Eleonora Orlandini und 8 weitere

American Journal of Medical Genetics Part A · 2025

DOI: 10.1002/ajmg.a.64168 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Sietse M Aukema und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Human Growth Hormone, Intellectual Disability, Abnormalities, Multiple, Tooth Abnormalities. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIHR Manchester Biomedical Research Centre, MRC Epigenomics of Rare Diseases Node, Manchester Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KBG syndrome is one of the most frequent neurodevelopmental disorders and is caused by ANKRD11 variants. Postnatal short stature is observed in ~50% of patients. Recombinant human growth hormone (rhGH) has become a valuable treatment for patients with growth hormone deficiency (GHD) along with Prader–Willi and Turner syndrome. Limited evidence suggests benefits for some patients with KBG syndrome, but systematic analysis and detailed phenotyping are lacking. In this study, we include six unpublished patients with KBG syndrome treated with rhGH and 22 patients from the literature. At treatment start, 43% had GHD. Median height before treatment was −2.9 standard deviation score (SDS) which increased to −1.8 SDS at the latest measurement. Moreover, half of the patients showed height gains of ≥ 1 SDS and 10/18 patients with short stature before treatment achieved heights within normal ranges following treatment or at the latest available measurement. Of interest, the difference between pre‐treatment height SDS and that at the latest measurement (∆HSDS) was comparable for patients with and without GHD. This study represents the largest group of patients with KBG syndrome treated with rhGH so far and suggests that rhGH treatment has a positive impact on height, as indicated by ∆HSDS, in a subset of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneIntellectual DisabilityAbnormalities, MultipleTooth AbnormalitiesMicrocephalyHumansFemaleChildMaleBody HeightAdolescentChild, PreschoolRepressor ProteinsPhenotypeRecombinant ProteinsPrader-Willi SyndromeTurner SyndromeFaciesBone Diseases, Developmental

Stichwörter der Autor:innen

ANKRD11KBGKBG syndromegrowth hormonegrowth hormone treatmentpersonalized medicineshort stature

Substanzen

Human Growth HormoneRepressor ProteinsANKRD11 protein, humanRecombinant Proteins

Autor:innen und Institutionen

  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Institute of Medical Genetics, University Medicine Oldenburg, Oldenburg, Germany.
  • Radboud University Medical Center, Nijmegen, the Netherlands.
  • Pediatrics Unit, IRCCS Azienda Ospedaliero, Universitaria di Bologna, Bologna, Italy.
  • Hunter Genetics, Waratah, Australia.
  • University of Newcastle, Callaghan, Australia.

ORCID-Profile: Sietse M Aukema, Kim Vandenput, Emanuela Scarano, Himanshu Goel, Lily Guo, Michiel Vanneste, Koen Devriendt, Nitash Zwaveling-Soonawala, Ilaria Parenti, Siddharth Banka, Elizabeth Wall, Gholson J Lyon, Karen J Low, Yvonne G van der Zwan, Charlotte W Ockeloen

Förderung

  • NIHR Manchester Biomedical Research Centre
  • MRC Epigenomics of Rare Diseases Node
  • Manchester Biomedical Research Centre

Zitieren

APA

Aukema, S. M., Vandenput, K., Scarano, E., Goel, H., Guo, L., Vanneste, M., Devriendt, K., Zwaveling-Soonawala, N., Kiewert, C., Kuechler, A., Parenti, I., Orlandini, E., de Boer, E., Banka, S., Wall, E., Lyon, G. J., Low, K. J., Geelen, J. M., van der Zwan, Y. G., & Ockeloen, C. W. (2025). Growth Hormone Treatment in Patients With KBG Syndrome: Novel Insights, Challenges and Recommendations From Six New Patients and Literature Review. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.64168

Vancouver

Aukema SM, Vandenput K, Scarano E, Goel H, Guo L, Vanneste M, et al. Growth Hormone Treatment in Patients With KBG Syndrome: Novel Insights, Challenges and Recommendations From Six New Patients and Literature Review. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.64168

BibTeX
@article{Aukema2025,
  author = {Aukema, Sietse M and Vandenput, Kim and Scarano, Emanuela and Goel, Himanshu and Guo, Lily and Vanneste, Michiel and Devriendt, Koen and Zwaveling-Soonawala, Nitash and Kiewert, Cordula and Kuechler, Alma and Parenti, Ilaria and Orlandini, Eleonora and de Boer, Elke and Banka, Siddharth and Wall, Elizabeth and Lyon, Gholson J and Low, Karen J and Geelen, Joyce M and van der Zwan, Yvonne G and Ockeloen, Charlotte W},
  title = {Growth Hormone Treatment in Patients With KBG Syndrome: Novel Insights, Challenges and Recommendations From Six New Patients and Literature Review},
  journal = {American Journal of Medical Genetics Part A},
  year = {2025},
  doi = {10.1002/ajmg.a.64168}
}
Kostenlos starten →